Abstract
The role of the oral BCL2 antagonist venetoclax in Waldenstrom macroglobulinemia (WM) is unknown. Immunophenotypic and genomic sequencing studies have shown that BCL2 is highly expressed and activated in WM cells. We initiated a phase II study to evaluate the safety and efficacy of venetoclax monotherapy in previously treated patients with WM (NCT02677324).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
